'
The related resources bookmark allows you to jump directly to other pages on the site that contain information directly related to the topics you're currently exploring.
Related Resources for this page:
- Biological Pathways
- Therapeutic Targets
- Pipeline Molecules
- Research Education
- Clinical Trials
- Future Directions
- Antibody-Drug conjugates
- Emerging therapeutic options
- Emerging therapeutic options
- VEGF expression in gastric cancer
- HER Signaling
- High VEGF expression
- VEGF and prognosis in multiple myeloma
- VEGF expression and liver metastases
- MVD and progression
- Hypoxic tumor environment promotes angiogenesis
- Serum VEGF as a clinical marker
- Regulation of VEGF expression
- VEGF expression in multiple myeloma
- VEGF pathways in multiple myeloma
- Summary
- VEGF and progression
- VEGF in bladder cancer
- VEGF in pancreatic cancer
- Summary
- Summary
- VEGF and MVD
- Summary
- VEGF and prognosis
- VEGF and prognosis in pancreatic cancer
- VEGF and tumor progression in gastric cancer
- VEGF and tumor progression in pancreatic cancer
- VEGF and progression in urothelial carcinoma
- VEGF in gastric cancer
- VEGF in multiple myeloma
- Apoptosis
- Bispecific Monoclonal Antibodies
- Glycoengineered Antibodies
- Emerging therapeutic options
- Emerging therapeutic options
- VEGF expression in gastric cancer
- HER Signaling
- High VEGF expression
- VEGF and prognosis in multiple myeloma
- VEGF expression and liver metastases
- MVD and progression
- Hypoxic tumor environment promotes angiogenesis
- Emerging therapeutic options
- Serum VEGF as a clinical marker
- Regulation of VEGF expression
- VEGF expression in multiple myeloma
- VEGF pathways in multiple myeloma
- Summary
- VEGF and progression
- VEGF in bladder cancer
- VEGF in pancreatic cancer
- Summary
- Summary
- VEGF and MVD
- Summary
- VEGF and prognosis
- VEGF and prognosis in pancreatic cancer
- VEGF and tumor progression in gastric cancer
- VEGF and tumor progression in pancreatic cancer
- VEGF and progression in urothelial carcinoma
- VEGF in gastric cancer
- VEGF in multiple myeloma
- Non-Antibody Biologics
- Apoptosis
- VEGF expression in gastric cancer
- High VEGF expression
- VEGF and prognosis in multiple myeloma
- VEGF expression and liver metastases
- MVD and progression
- Hypoxic tumor environment promotes angiogenesis
- Serum VEGF as a clinical marker
- Regulation of VEGF expression
- VEGF expression in multiple myeloma
- What are the strategies for inhibiting the VEGF pathway?
- VEGF pathways in multiple myeloma
- Summary
- VEGF and progression
- VEGF in bladder cancer
- VEGF in pancreatic cancer
- Summary
- Summary
- VEGF and MVD
- Summary
- VEGF and prognosis
- VEGF and prognosis in pancreatic cancer
- VEGF and tumor progression in gastric cancer
- VEGF and tumor progression in pancreatic cancer
- VEGF and progression in urothelial carcinoma
- VEGF in gastric cancer
- VEGF in multiple myeloma
- Targeted Small Molecules
- Apoptosis
- Emerging therapeutic options
- Emerging therapeutic options
- VEGF expression in gastric cancer
- Gastric Cancer
- High VEGF expression
- VEGF and prognosis in multiple myeloma
- VEGF expression and liver metastases
- MAPK Signaling
- Melanoma
- MVD and progression
- Hypoxic tumor environment promotes angiogenesis
- Multiple Myeloma
- Emerging therapeutic options
- PI3K Inhibitor (GDC-0941)
- Other Tumor Types
- Serum VEGF as a clinical marker
- PI3K/Akt/mTOR Signaling
- Slide decks and videos
- Regulation of VEGF expression
- VEGF expression in multiple myeloma
- What are the strategies for inhibiting the VEGF pathway?
- VEGF pathways in multiple myeloma
- Summary
- VEGF and progression
- VEGF in bladder cancer
- VEGF in pancreatic cancer
- Summary
- Summary
- VEGF and MVD
- Summary
- VEGF and prognosis
- VEGF and prognosis in pancreatic cancer
- VEGF and tumor progression in gastric cancer
- VEGF and tumor progression in pancreatic cancer
- VEGF and progression in urothelial carcinoma
- VEGF in gastric cancer
- VEGF in multiple myeloma
- Traditional Monoclonal Antibodies
- Anti-EGFL7
- B-cell Surface Proteins
- Glossary
- Emerging therapeutic options
- Emerging therapeutic options
- VEGF expression in gastric cancer
- Gastric Cancer
- HER Signaling
- High VEGF expression
- VEGF and prognosis in multiple myeloma
- VEGF expression and liver metastases
- Melanoma
- MVD and progression
- Hypoxic tumor environment promotes angiogenesis
- Emerging therapeutic options
- Serum VEGF as a clinical marker
- Angiogenic Signaling
- Slide decks and videos
- Regulation of VEGF expression
- VEGF expression in multiple myeloma
- What are the strategies for inhibiting the VEGF pathway?
- VEGF pathways in multiple myeloma
- Summary
- VEGF and progression
- VEGF in bladder cancer
- VEGF in pancreatic cancer
- Summary
- Summary
- VEGF and MVD
- Summary
- VEGF and prognosis
- VEGF and prognosis in pancreatic cancer
- VEGF and tumor progression in gastric cancer
- VEGF and tumor progression in pancreatic cancer
- VEGF and progression in urothelial carcinoma
- VEGF in gastric cancer
- VEGF in multiple myeloma
- Antibody-Drug conjugates
Share
Renal Cell Carcinoma
Disease Information
Genentech BioOncology is dedicated to advancing the science of renal cell carcinoma therapy through comprehensive research programs and education. Renal cell carcinoma forms in the renal microtubules that filter blood and remove waste products.1
Renal Cell Cancer Statistics
- In 2010, an estimated 58,240 Americans were diagnosed with renal cancer. Of these diagnoses, 92% were renal cell carcinoma, 7% were renal pelvis carcinoma, and 7% were Wilms tumor, a childhood cancer2
- Since 1975, incidence of kidney cancer has increased by 1.8% each year in men and 2.4% in women2
- Renal cancer mortality in 2010 was about 13,040. Death rates for renal cancer have been decreasing2
- Mortality in women has decreased by 0.6% per year since 19922
- Mortality in men has decreased by 1.5% per year since 20022
Renal Cell Cancer Epidemiology
- Risk factors include smoking; obesity; hypertension; workplace exposure to asbestos, cadmium, certain herbicides, benzene, and organic solvents; male gender (possibly related to smoking and workplace exposure to toxins); advanced renal disease; and family history of renal cell carcinoma3
- Certain rare hereditary diseases greatly increase the risk of renal cancer (von Hippel-Lindau syndrome, Birt-Hogg-Dube syndrome, and renal oncocytoma)3
- The 5-year relative survival rate for renal cell carcinoma is 70%2
Renal Cell Cancer Symptoms
Early renal cancer usually has no symptoms. As the tumor progresses, it may cause hematuria, a pain or lump in the lower back or abdomen, fatigue, weight loss, fever, or edema in the legs and ankles.2
Other links to renal cell carcinoma disease information
These links give a sampling of other sites offering information on renal cell carcinoma, which you may find useful in your practice.
- National Cancer Institute at National Institutes of Health, Kidney Cancer
- ASCO Cancer Portals - Genitourinary Cancers
- Cancer Facts & Figures
Unless otherwise indicated, Genentech, Inc. is neither affiliated with nor endorses any of the organizations listed.
References:
- 1.
- US Department of Health and Human Services. National Cancer Institute. www.cancer.gov/cancertopics/types/kidney. Accessed April 13, 2011.
- 2.
- American Cancer Society. Cancer Facts & Figures 2010. www.cancer.org/acs/groups/content/@epidemiologysurveilance/
documents/document/acspc-026238.pdf. Accessed April 14, 2011. - 3.
- US Department of Health and Human Services. National Cancer Institute Web site. www.cancer.gov/cancertopics/wyntk/kidney/page4. Accessed April 13, 2011.